Aztreonam-avibactam combination restores susceptibility of aztreonam in dual-carbapenemase-producing enterobacteriaceae

Antimicrobial Agents and Chemotherapy

Volumn 62, Issue 8, 2018, Pages

  Chew, Ka Lip ^a   Tay, Michelle K L ^a   Cheng, Bernadette ^a   Lin, Raymond T P ^a,b   Octavia, Sophie ^b   Teo, Jeanette W P ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b MINISTRY OF HEALTH   (Singapore)

Author keywords

Aztreonam avibactam; Carbapenem resistant Enterobacteriaceae; Carbapenemase; Meropenem vaborbactam; Multidrug resistant bacteria

Indexed keywords

CARBAPENEMASE; ANTIINFECTIVE AGENT; AVIBACTAM; AZABICYCLO DERIVATIVE; AZTREONAM; BACTERIAL PROTEIN; BETA LACTAMASE; ISOENZYME;

ARTICLE; BACTERIAL GENE; CITROBACTER FREUNDII; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; NONHUMAN; PRIORITY JOURNAL; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; DRUG COMBINATION; DRUG EFFECT; ENTEROBACTERIACEAE INFECTION; ENZYMOLOGY; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; SINGAPORE;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; AZTREONAM; BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CITROBACTER FREUNDII; DRUG COMBINATIONS; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE INFECTIONS; ESCHERICHIA COLI; GENE EXPRESSION; HUMANS; ISOENZYMES; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; SINGAPORE;

EID: 85052024698     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00414-18     Document Type: Article

References (15)

1. Lomovskaya O, Sun D, Rubio-Aparicio D, Nelson K, Tsivkovski R, Griffith DC, Dudley MN. 2017. Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae. Antimicrob Agents Chemother 61:e01443-17. https://doi.org/10.1128/AAC.01443-17.
2. Bush K. 2015. A resurgence of beta-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int J Antimicrob Agents 46:483–493. https://doi.org/10.1016/j.ijantimicag.2015.08.011.
3. Vasoo S, Cunningham SA, Cole NC, Kohner PC, Menon SR, Krause KM, Harris KA, De PP, Koh TH, Patel R. 2015. In vitro activities of ceftazidime-avibactam, aztreonam-avibactam, and a panel of older and contemporary antimicrobial agents against carbapenemase-producing Gram-negative bacilli. Antimicrob Agents Chemother 59:7842–7846. https://doi.org/10.1128/AAC.02019-15.
4. Castanheira M, Rhomberg PR, Flamm RK, Jones RN. 2016. Effect of the -lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 60:5454–5458. https://doi.org/10.1128/AAC.00711-16.
5. Marimuthu K, Venkatachalam I, Khong WX, Koh TH, Cherng BPZ, La MV, De PP, Krishnan PU, Tan TY, Choon RFK, Pada SK, Lam CW, Ooi ST, Deepak RN, Smitasin N, Tan EL, Lee JJ, Kurup A, Young B, Sim NTW, Thoon KC, Fisher D, Ling ML, Ang BSP, Teo Y-Y, Hsu LY, Lin RTP, Ong RTH, Teo J, Ng OT. 2017. Clinical and molecular epidemiology of carbapenem-resistant Enterobacteriaceae among adult inpatients in Singapore. Clin Infect Dis 64:S68 –S75. https://doi.org/10.1093/cid/cix113.
6. Khan AU, Maryam L, Zarrilli R. 2017. Structure, genetics and worldwide spread of New Delhi metallo-beta-lactamase (NDM): a threat to public health. BMC Microbiol 17:101. https://doi.org/10.1186/s12866-017-1012-8.
7. Balm MND, La M-V, Krishnan P, Jureen R, Lin RTP, Teo JWP. 2013. Emergence of Klebsiella pneumoniae co-producing NDM-type and OXA-181 carbapenemases. Clin Microbiol Infect 19:E421–E423. https://doi .org/10.1111/1469-0691.12247.
8. Queenan AM, Bush K. 2007. Carbapenemases: the versatile -lactamases. Clin Microbiol Rev 20:440 – 458. https://doi.org/10.1128/CMR.00001-07.
9. Evans BA, Amyes SGB. 2014. OXA -lactamases. Clin Microbiol Rev 27:241–263. https://doi.org/10.1128/CMR.00117-13.
10. KPC into bacterial species beyond Klebsiella pneumoniae and in vitro susceptibility to ceftazidime-avibactam and aztreonam-avibactam. Antimicrob Agents Chemother 60:4490–4500. https://doi.org/10.1128/AAC.00107-16.
11. Sader HS, Mendes RE, Pfaller MA, Shortridge D, Flamm RK, Castanheira M. 2018. Antimicrobial activities of aztreonam-avibactam and comparator agents against contemporary (2016) clinical Enterobacteriaceae isolates. Antimicrob Agents Chemother 62:e01856-17. https://doi.org/10.1128/AAC.01856-17.
12. Karlowsky JA, Kazmierczak KM, de Jonge BLM, Hackel MA, Sahm DF, Bradford PA. 2017. In vitro activity of aztreonam-avibactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated by clinical laboratories in 40 countries from 2012 to 2015. Antimicrob Agents Chemother 61:e00472-17. https://doi.org/10.1128/AAC.00472-17.
13. Biedenbach DJ, Kazmierczak K, Bouchillon SK, Sahm DF, Bradford PA. 2015. In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013. Antimicrob Agents Chemother 59:4239 – 4248. https://doi.org/10.1128/AAC.00206-15.
14. Teo J, Ngan G, Balm M, Jureen R, Krishnan P, Lin R. 2012. Molecular characterization of NDM-1 producing Enterobacteriaceae isolates in Singapore hospitals. West Pacific Surveill Response 3:19–24. https://doi.org/10.5365/wpsar.2011.2.4.010.
15. CLSI. 2018. Performance standards for antimicrobial susceptibility testing, 28th ed., M100-S28E. CLSI, Wayne, PA.